November 9, 2025 — Today is a day to stop and think about more than a decade of working with an exceptional leader in obesity medicine: Fatima Cody Stanford. A new PBS feature brings us to reflect upon this. In a quarter century of working in obesity, we have had the privilege of knowing and working with many […]
June 29, 2025 — It is jarring to hear much talk about making America great while we see signs that American biotech leadership is fading. Until now, America has been the unquestioned leader in biotechnology innovation. But hard data suggests that China is chipping away at that. Recent actions by the U.S. federal government seem to be opening the […]
February 26, 2025 — Just days after an FDA ruling that will force most compounders out of the market for obesity medicines, Eli Lilly announced yet another carefully calibrated price cut for its Zepbound brand of tirzepatide. These are direct-to-consumer prices for the product packaged in vials. Specifically, Lilly offered up two new, higher dose vials at a reduced […]
August 27, 2024 — That was quick. At about 6 am today, we posted to say that obesity drug prices are stuck in the spotlight. “Bold leadership on obesity drug pricing and access to care is the only thing that will bring relief from this uncomfortable spotlight,” we wrote. Before the end of the hour, Lilly took the cue. […]
July 19, 2020 — People adapt. This is a powerful fact of human psychology that hands us the problem of shifting baselines. When circumstances change, people come to accept a new normal. Even jarring changes, such as the blitz on London during World War II, might shock people at first. Yet after a time, people come to accept a […]
